Dr Reddy`s Laboratories on Wednesday announced the launch of Remdesivir under the brand name Redyx for Indian markets.

The launch is part of a licensing agreement with Gilead Sciences Inc that grants Dr Reddy`s the right to register, manufacture and sell Remdesivir, a potential treatment for COVID-19, in 127 countries including India.

Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalised with severe symptoms.

 

Dr Reddy`s Redyx is available in the strength of 100 mg vial.

 

"We will continue our efforts to develop products that address significant unmet needs of patients," said M V Ramana, Chief Executive Officer for branded markets (India and emerging markets) at Dr. Reddy`s.

"The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from Covid-19 in India," he said in a statement.

Last month, Dr. Reddy`s announced the launch of Avigan (Favipiravir) 200 mg tablets in India for the treatment of patients with mild to moderate COVID-19 disease.

The launch was a part of a global licensing agreement with Fujifilm Toyama Chemical that grants Dr. Reddy`s exclusive rights to manufacture, sell and distribute Avigan tablets in India.